Navigation Links
Oncology Metrics Launches the National Practice Benchmark: One in a Series of Initiatives to Help Community Oncology Practices Better Measure Operational and Financial Performance
Date:2/6/2008

DALLAS and FORT WORTH, Texas, Feb. 6 /PRNewswire/ -- Oncology Metrics, a business that develops products and services to help accelerate advancements in the treatment of cancer, today announced the launch of the first annual National Practice Benchmark, an initiative to assist community oncology practices understand critical operating measures.

This benchmark initiative will be open to all community-based oncology practices nationally. Practices of all size are invited to participate. The survey will be sent to administrators and physicians via e-mail and the data collected using an online survey instrument, a quick and efficient method for capturing the data. The survey will take approximately 30 minutes to complete.

The first 200 respondents will be eligible for gift cards ranging from $25.00 to $50.00 and all respondents who complete the survey will be placed in a drawing for a new iPhone from Apple. In addition, respondents will receive an electronic copy of the survey results. The survey results will also be submitted for publication in a national oncology business journal.

Benchmarking is widely recognized as the best and most efficient way to find opportunities to improve your practice and monitor progress after corrective action is taken. Benchmarks have been used to reduce costs and improve revenue, and discover new product and service lines that can be used to make your practice more effective and efficient. Better performing practices continuously benchmark internally and externally. Tom Barr, COO of Oncology Metrics commented, "If you don't measure, you are just guessing."

Interested practices may contact Oncology Metrics directly to request participation.

About Oncology Metrics

Oncology Metrics is a service and data business for the oncology community that develops products and services to help accelerate advancements in the treatment of cancer. Oncology Metrics has built three distinct networks of commun
'/>"/>

SOURCE Oncology Metrics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
4. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
5. US Oncology to Report 2007 Third Quarter Earnings Results
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
8. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
9. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
10. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
11. National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National Greening Your School Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2008)...umption of illicit or noncommercial alcohol is wid...s significantly to the global burden of disease, a...ernational Center for Alcohol Policies (ICAP). The...l, defined as traditional beverages produced for h...feit or unregistered products, in three regions: s...
(Date:11/20/2008)... results in review of national program , ...l cancer screening detects 40 percent of cancers a...e, say Finnish Cancer Registry researchers. , T...rmine how sensitive Finland,s colorectal cancer sc...sease. Half the people were assigned to a screenin...
(Date:11/20/2008)...spiratory disease , , THURSDAY, Nov. 20 ...ng ovulation may explain why women with cystic fib...tory disease, researchers at the University of Nor..., published in the Nov. 20 issue of the Journal o... reduce estrogen levels, such as tamoxifen, might ...
(Date:11/20/2008)... The National Minority Quality Forum (NMQF) today ...t decision to develop a Health Insurer Code of Con... to join the Forum in encouraging adoption and com...sicians and lawyers -- even politicians -- follow ...nt and Chief Executive Officer of the Forum. "It,s...
Breaking Medicine News(10 mins):Health News:Report finds extensive use of illicit alcohol 2Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 3Health News:National Minority Quality Forum Applauds AMA's Health Insurer Code of Conduct 2
... planned in Edmonton’s Capital Health Region.// As...erson is recorded whenever he or she visits a hosp...ed in a central database. This information can fur...t the illness if found. If diabetes is not treate...
...ns high pressure in the arteries. High blood press...ler’ because one can have it for years without kno...his blood pressure reading is around 120/80. Canad...ic reading between 130 and 139, and a diastolic re...
...tical giant, is finalizing its plan of action, to ...erck & Co.'s Gardasil, in a bid to establish the m...e study, which will be conducted in the United Sta...responses of women aged 18 to 26 years old, to two...
...point to lung cancer, say researchers at the Unive...eloping an inexpensive and non-invasive gene probe...nt and former smokers. In the January 15 issue of ...ers report that their fledgling test, designed to ...
Other Medicine News:Health News:Slightly High Blood Pressure is Also Hazardous 2Health News:Simple Test Detects Genetic Signs of Lung Cancer in a Patient’s Sputu 2Health News:Simple Test Detects Genetic Signs of Lung Cancer in a Patient’s Sputu 3
(Date:11/20/2008)...ILADELPHIA, Nov. 20 Glaxo... United States Food and Drug Administration (FDA) ...ombopag) for the treatment of thrombocytopenia in ...ytopenic purpura (ITP) who have had an insufficien...splenectomy. The approval is a significant milesto...
(Date:11/20/2008)... Milk. It does a body good. And,n...ht. After years of,research, scientists at OncoNu...,s milk that stimulate the body,s own production o...a News Release, go to:, http://www.prnewswire.com/...ing new cancer therapies, the chief scientist, Dr....
(Date:11/20/2008)... Radius Health ("Radius") announced...n to its second institutional financing round, inc... and the total amount raised since the company,s i...onal investors participated in the financing, led ... Capital, The Wellcome Trust, HealthCare Ventures,...
(Date:11/20/2008)...er 20 The Scandinavian-based drug,... results of studies on its,lead antimicrobial can...DC,the studies showed that the novel lytic pepti..., significantly better towards killing Staphylococ...ed gold standard drugs. In,addition to this it ha...
Breaking Medicine Technology:FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Melanomas may appear noticeably different than other moles 9848 1Melanomas may appear noticeably different than other moles 9848 2Exercise Program Eases Arthritis 9844 1Exercise Program Eases Arthritis 9844 2Greenway Experiences Quick Success in the Community EHR Marketplace by Securing Contracts with 10 Community Based Health Organizations 9840 1Greenway Experiences Quick Success in the Community EHR Marketplace by Securing Contracts with 10 Community Based Health Organizations 9840 2Greenway Experiences Quick Success in the Community EHR Marketplace by Securing Contracts with 10 Community Based Health Organizations 9840 3Greenway Experiences Quick Success in the Community EHR Marketplace by Securing Contracts with 10 Community Based Health Organizations 9840 4Greenway Experiences Quick Success in the Community EHR Marketplace by Securing Contracts with 10 Community Based Health Organizations 9840 5Benefitfocus 28R 29 Expands Reach to Consumers With ConnectYourCare Partnership 9836 1Benefitfocus 28R 29 Expands Reach to Consumers With ConnectYourCare Partnership 9836 2Benefitfocus 28R 29 Expands Reach to Consumers With ConnectYourCare Partnership 9836 3
...ro-Pharmaceuticals,Inc. (Amex: PRW), a company "A...ated the progress of its Phase II,clinical trial f...e,colorectal cancer patients who are unable to tol... II clinical trial for first-line,treatment of bil...ns may represent orphan drug status for DAVANAT(R)...
...ugar Biotechnology,Inc. (OTCBB:CGRB) today announ... Company,s prostate cancer drug candidate CB7630,(...n Society for,Medical Oncology (ESMO) Conference, ...land. The data were presented in two oral and,post... session for,genitourinary (prostate) cancer that ...
Other Medicine Technology:Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 2Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 3Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 4Pro-Pharmaceuticals Updates Progress of Clinical Trials &,Davanat 505 (b)(2) Filings 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 2Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 3Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 4Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 5Cougar Biotechnology Announces Presentation of Positive CB7630,Clinical Data at ESMO Conference 6
Ammonia/Alcohol Control is intended as a means of monitoring various ammonia and ethanol assay methods. This ready-to-use, three-level control is targeted at clinically significant levels of ammonia
This unassayed control is intended as a means of monitoring manual and automated assay methods used for the quantitation of oxalate in human urine samples. This control is ready-to-use liquid, requir
Microbumin is a two-level control compatible with popular strips such as Clinitek Microalbumin Reagent Strips and Roche Micral test strips. This control is also suitable for turbidimetric immunoassay
...rol monitors the performance of Abuscreen ONLINE, ...ening methods. This control meets current revised ...Mental Health Services Administration (SAMSHA). Le...s below screening cut-off levels (negative thresho...
Medicine Products: